Blueprint Medicines Corp (BPMC)
107.19
+0.19
(+0.18%)
USD |
NASDAQ |
May 03, 16:00
107.20
+0.01
(+0.01%)
After-Hours: 20:00
Blueprint Medicines Profit Margin (Quarterly): -154.1% for Dec. 31, 2023
Profit Margin (Quarterly) Chart
Historical Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -154.1% |
| September 30, 2023 | -236.4% |
| June 30, 2023 | -230.7% |
| March 31, 2023 | -204.7% |
| December 31, 2022 | -409.1% |
| September 30, 2022 | -201.8% |
| June 30, 2022 | -437.0% |
| March 31, 2022 | -169.0% |
| December 31, 2021 | -297.8% |
| September 30, 2021 | -484.7% |
| June 30, 2021 | -397.3% |
| March 31, 2021 | -462.2% |
| December 31, 2020 | -251.2% |
| September 30, 2020 | 85.08% |
| June 30, 2020 | -1.48K% |
| March 31, 2020 | -1.80K% |
| December 31, 2019 | -128.7% |
| September 30, 2019 | -1.03K% |
| Date | Value |
|---|---|
| June 30, 2019 | -1.95K% |
| March 31, 2019 | -11.97K% |
| December 31, 2018 | -7.78K% |
| September 30, 2018 | -6.64K% |
| June 30, 2018 | -65.27% |
| March 31, 2018 | -5.93K% |
| December 31, 2017 | -3.01K% |
| September 30, 2017 | -467.3% |
| June 30, 2017 | -567.3% |
| March 31, 2017 | -479.1% |
| December 31, 2016 | -276.5% |
| September 30, 2016 | -273.3% |
| June 30, 2016 | -267.4% |
| March 31, 2016 | -226.1% |
| December 31, 2015 | -336.0% |
| September 30, 2015 | -369.0% |
| June 30, 2015 | -483.1% |
| March 31, 2015 | -1.77K% |
Profit Margin Definition
Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.
Profit Margin (Quarterly) Range, Past 5 Years
-1.95K%
Minimum
Jun 2019
85.08%
Maximum
Sep 2020
-539.0%
Average
-297.8%
Median
Dec 2021
Profit Margin (Quarterly) Benchmarks
| Apellis Pharmaceuticals Inc | -60.51% |
| Alnylam Pharmaceuticals Inc | -13.34% |
| Ionis Pharmaceuticals Inc | -2.85% |
| Madrigal Pharmaceuticals Inc | -- |
| Sarepta Therapeutics Inc | 8.74% |
Profit Margin (Quarterly) Related Metrics
| Return on Equity | -161.1% |
| Return on Assets | -43.47% |
| Return on Invested Capital | -102.7% |
| Gross Profit Margin (Quarterly) | 99.64% |
| Operating Margin (Quarterly) | -146.1% |
| Return on Net Operating Assets | -292.2% |